Nivolumab/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nivolumab/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF THERAPEUTICS
Volume 30, Issue 6, Pages e526-e534
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2023-11-03
DOI
10.1097/mjt.0000000000001680
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparative efficacy and safety of immune checkpoint inhibitors for unresectable advanced melanoma: A systematic review and network meta-analysis
- (2023) Yan Li et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
- (2023) Paolo Antonio Ascierto et al. JOURNAL OF CLINICAL ONCOLOGY
- Relatlimab-Nivolumab: A Practical Overview for Dermatologists
- (2023) Nikita Mullick et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022
- (2023) Paolo A. Ascierto et al. Journal of Translational Medicine
- The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma
- (2023) Lea Jessica Albrecht et al. Current Oncology Reports
- Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis
- (2023) Andrea Boutros et al. EUROPEAN JOURNAL OF CANCER
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- (2022) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer
- (2022) An-Ping Shi et al. Frontiers in Immunology
- Relatlimab plus nivolumab beneficial for previously untreated metastatic or unresectable melanoma
- (2022) Kate O’Rourke CANCER
- Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)
- (2022) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma
- (2022) Allison L. Phillips et al. ANNALS OF PHARMACOTHERAPY
- Neoadjuvant relatlimab and nivolumab in resectable melanoma
- (2022) Rodabe N. Amaria et al. NATURE
- Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination with Nivolumab
- (2022) Kent Thudium et al. Cancer Immunology Research
- Relatlimab and nivolumab in the treatment of melanoma
- (2022) Lewis Au et al. CELL
- NCT04552223: A phase II study of nivolumab plus BMS-986016 (relatlimab) in patients with metastatic uveal melanoma (UM) (CA224-094).
- (2021) Jose Lutzky et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy
- (2021) Claudia Trojaniello et al. Frontiers in Oncology
- LAG-3: from molecular functions to clinical applications
- (2020) Takumi Maruhashi et al. Journal for ImmunoTherapy of Cancer
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
- (2015) Sonja Kleffel et al. CELL
- LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
- (2014) F. Xu et al. CANCER RESEARCH
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
- (2011) P. Hemon et al. JOURNAL OF IMMUNOLOGY
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
- (2008) Shawn D Blackburn et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now